Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof
View Patent ↗The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
1. An isolated anti-Nogo-66 receptor (NgR) monoclonal antibody comprising a heavy chain variable region of SEQ ID NO:3 and a light chain variable region of SEQ ID NO:4.
2. The isolated anti-NgR monoclonal antibody of claim 1 , wherein the antibody comprises a kappa light chain constant region.
3. The isolated anti-NgR monoclonal antibody of claim 1 or 2 , wherein the antibody comprises a heavy chain constant region of an IgG isotype.
4. The isolated anti-NgR monoclonal antibody of claim 3 , wherein the IgG isotype is an IgG2a isotype.
5. The isolated anti-NgR monoclonal antibody of claim 1 , wherein the antibody is selected from the group consisting of a mouse antibody, a humanized antibody, a fully human, and a chimeric antibody.
6. The isolated anti-NgR monoclonal antibody of claim 1 , wherein the antibody is human.
7. A pharmaceutical composition comprising the anti-NgR monoclonal antibody of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.
8. An isolated anti-Nogo-66 receptor (NgR) monoclonal antibody comprising a heavy chain variable region of SEQ ID NO:5 and a light chain variable region of SEQ ID NO:6.
9. The isolated anti-NgR monoclonal antibody of claim 8 , wherein the antibody comprises a kappa light chain constant region.
10. The isolated anti-NgR monoclonal antibody of claim 8 or 9 , wherein the antibody comprises a heavy chain constant region of an IgG isotype.
11. The isolated anti-NgR monoclonal antibody of claim 10 , wherein the IgG isotype is an IgG2a isotype.
12. The isolated anti-NgR monoclonal antibody of claim 8 , wherein the antibody is selected from the group consisting of a mouse antibody, a humanized antibody, a fully human, and a chimeric antibody.
13. The isolated anti-NgR monoclonal antibody of claim 12 , wherein the antibody is human.
14. A pharmaceutical composition comprising the anti-NgR monoclonal antibody of any one of claims 8 to 13 and a pharmaceutically acceptable carrier.